Pharmafile Logo

Tobi Podhaler

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

National Institute for Health and Care Excellence NICE logo

NICE recognises Smartinhaler as best practice for asthma care

Digital monitoring device proven to increase adherence and reduce hospital visits

- PMLiVE

Wales unveils ‘sensible’ £80m medicines access fund

New scheme hopes to provide greater consistency and accelerate availability by eight weeks

Novartis building

Novartis boosts cardiovascular pipeline with $1bn Ionis deal

Gains rights to two lipoprotein-targeting drugs currently in early-stage clinical development 

- PMLiVE

Novartis launches heart failure social network

Together in HF is the first digital effort of its kind for the condition

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Greece steps up Novartis corruption probe after suicide attempt

Accelerates investigation into whether Novartis paid bribes to doctors and civil servants to drive sales

Novartis day

Novartis buys two firms in pre-Christmas shopping spree

Acquires eye disease specialist Encore Vision and NASH drug firm Conatus Pharma

Deal Watch November 2016

Actelion, Allergan, Johnson & Johnson, Novartis and more feature in this month's pharma deals round-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links